ValiRx Plc (VAL) Earns Corporate Rating from Northland Securities
ValiRx Plc (LON:VAL)‘s stock had its “corporate” rating reissued by equities researchers at Northland Securities in a research report issued to clients and investors on Thursday.
Separately, Beaufort Securities reiterated a “speculative buy” rating on shares of ValiRx Plc in a report on Thursday, August 11th.
ValiRx Plc (LON:VAL) opened at 7.20 on Thursday. ValiRx Plc has a 1-year low of GBX 5.75 and a 1-year high of GBX 28.01. The firm’s market capitalization is GBX 3.77 million. The firm has a 50-day moving average price of GBX 7.57 and a 200-day moving average price of GBX 8.57.
ValiRx Plc Company Profile
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
Receive News & Stock Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related stocks with our FREE daily email newsletter.